(Q36642651)

15 August 2017

1 reference

title

Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan (English)

1 reference

15 August 2017

3

Thomas Unger

1 reference

15 August 2017

Matthias Goebel

1

1 reference

15 August 2017

Markus Clemenz

series ordinal

2

1 reference

15 August 2017

publication date

1 September 2006

1 reference

Expert Review of Cardiovascular Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

4

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

615-629

1 reference

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

The role of the renin-angiotensin system in the development of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Angiotensin AT1/AT2 receptors: regulation, signalling and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Comparison of angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

PPAR gamma, 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

PPARs: therapeutic targets for metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

PPAR(gamma) and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

The Clinical Significance of PPAR Gamma Agonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Thiazolidinediones in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Therapeutic roles of peroxisome proliferator-activated receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Adiponectin: action, regulation and association to insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Adiponectin, obesity, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Telmisartan: a review of its use in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Sustained antihypertensive activity of telmisartan compared with valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Blood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinopril.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized,

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Telmisartan/hydrochlorothiazide: a new fixed dose combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Evolving strategies for the use of combination therapy in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

The role of combination therapy in the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Safety of telmisartan in patients with arterial hypertension : an open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

The ongoing telmisartan alone and in combination with ramipril global endpoint trial program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

The metabolic syndrome: cluster with a self-fulfilling loop?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Possible beneficial effect of telmisartan on glycemic control in diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. A randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Effect of telmisartan/hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Different effect of antihypertensive drugs on conduit artery endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) i

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

The ONTARGET/TRANSCEND Trial Programme: baseline data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Angiotensin II receptor antagonist treatment during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Metabolic syndrome: a clinical and molecular perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Methods to improve medication adherence in patients with hypertension: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Tolerability and treatment compliance with angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Clinical pharmacokinetics of candesartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.5.615

21 January 2018

Identifiers

DOI

10.1586/14779072.4.5.615

1 reference

15 August 2017

1 reference